Search

Gels are used in the oilfield. For example, during oil recovery, organogels are pumped underground into fractures within oil‐bearing rock, so as to block fluid flow. However, after several days, the gels must be degraded (liquefied) to enable oil extraction through the fractures. To degrade gels, 'degrading agents' as well as external stimuli have been examined. Here, a concept is demonstrated that avoids external agents and stimuli: self‐degrading organogels based on the self‐assembly of molecular gelators. The gels are a) extremely robust (free standing solids) at time t = 0 and (b) degrade spontaneously into a sol after a set time t = tdegr that can be minutes, hours, or days. These properties are achieved by combining two readily available molecules — the organogelator (1,3:2,4)‐dibenzylidene sorbitol (DBS) and an acid (e.g., hydrochloric acid, HCl) — in an organic solvent. DBS self‐assembles into nanoscale fibrils, which connect into a 3‐D network, thereby gelling the solvent. The acid type and concentration set the value of tdegr at a given temperature. Degradation occurs because the acid slowly hydrolyzes the acetals on DBS, thereby converting DBS into small molecules that cannot form fibrils. DBS gels with a pre‐programmed "degradation clock" can be made with both polar and non‐polar organic solvents. The concept can be a game‐changer for oil recovery as it promises to make it safer, more efficient, and sustainable. [ABSTRACT FROM AUTHOR]

Background: The efficacy of a combination of nimotuzumab, a humanized monoclonal antibody to the epidermal growth factor receptor, with chemoradiation in locally advanced head and neck squamous cell carcinoma (HNSCC) was evaluated in a phase II study. Methods: Patients with stage III/IV HNSCC received 3‐weekly cisplatin 100 mg/m2 for three cycles and weekly nimotuzumab 200 mg for 8 weeks concurrently with radiotherapy. Primary endpoint was best overall response (BOR) and secondary endpoint was progression‐free survival (PFS). Results: Thirty‐seven patients were included; the majority were Chinese (76%), male (89%), and had stage IVA/IVB HNSCC (92%). BOR of complete and partial response was seen in 22/37 (59%) and 10/37 (27%) patients, respectively. Median PFS was 17.5 months (95% CI: 11.1–54.5) and 3‐year PFS was 40.4% (95% CI: 24.3–55.9). The frequency and type of adverse events observed were similar to standard chemoradiation. Conclusion: The combination of nimotuzumab with cisplatin and radiotherapy was safe and achieved high response rates in HNSCC. [ABSTRACT FROM AUTHOR]

BACKGROUND The current study was performed to report the long-term results of a trial comparing concurrent chemotherapy and radiotherapy (CCRT) with surgery and adjuvant radiotherapy (RT) in patients with stage III/IV nonmetastatic head and neck squamous cell carcinoma. METHODS Patients with stage III/IV resectable head and neck squamous cell carcinoma were randomized to surgery followed by RT or CCRT. The trial was halted prematurely due to poor accrual. Human papillomavirus status was tested on archival material using polymerase chain reaction sequencing. RESULTS Of the total of 119 patients, 60 patients were randomized to primary surgery (S arm) and 59 patients were randomized to CCRT (C arm). Human papillomavirus status was tested in 75 patients, and only 3 were found to be positive. The median follow-up for surviving patients was 13 years. Analysis of the entire cohort demonstrated no statistically significant difference in overall survival and disease-specific survival (DSS): 5-year rates were 45% versus 35% for overall survival ( P = .262) and 56% versus 46% for DSS ( P = .637) for the S arm and C arm, respectively. Analysis by subsites indicated that this difference favoring the S arm was mainly driven by survival data among patients with cancers of the oral cavity and maxillary sinus. For patients with oral cavity cancer, survival was significantly better in those who underwent primary surgery compared with CCRT; the 5-year DSS rate was 68% versus 12% for the S arm and C arm, respectively ( P = .038). For patients with cancers of the maxillary sinus, the 5-year DSS rate was 71% for patients on the S arm and 0% for patients on the C arm ( P = .05). CONCLUSIONS These long-term results demonstrate a significant advantage for primary surgery in patients with cancers of the oral cavity or maxillary sinus, providing strong support for primary surgery as the main modality of treatment for these subsites. In other subsites, CCRT and surgery with adjuvant RT were found to demonstrate similar efficacy for survival in patients with advanced resectable tumors. Cancer 2015;121:1599-1607. © 2015 American Cancer Society. [ABSTRACT FROM AUTHOR]

Background. The aim of this study was to review our experience and demonstrate the safety of intracavitary brachytherapy (ICB) in patients with nasopharyngeal carcinoma (NPC). Methods. Hundred seventy-eight patients with early T1-2b disease underwent radical external beam radiation therapy (EBRT) followed by ICB boost. The primary tumor received 66 Gy of EBRT over 33 fractions using 6 or 10 MV photons. ICB insertions were performed 1 week later, delivering 10 Gy in 2 fractions over 8 days. Kaplan-Meier survival analyses were used to calculate the actuarial 5-year overall survival (OS), cause-specific survival, local control, and disease-free survival (DFS). Results. Five-year local control rates were 91.6%. OS, DFS, and cause-specific survival were estimated to be 85.25%, 81.7%, and 87.9%, respectively. Median follow-up was 86 months. There were no documented serious complications noted with ICB. Conclusion. ICB boost supplementing radical EBRT is an excellent method of enhancing local control for patients with NPC with early T1-2b disease. © 2009 Wiley Periodicals, Inc. Head Neck, 2009 [ABSTRACT FROM AUTHOR]

Background Retropharyngeal lymph node (RLN) staging in nasopharyngeal carcinoma (NPC) can be controversial. Methods We retrospectively reviewed all patients with T2–4, N0–1 NPC treated between 1992 and 1994 to examine if RLN metastasis resulted in an increased incidence of distant metastases. Results Of the 667 patients with NPC, 395 had T2–4, N0–1 disease, 140 had N0, and 255 had N1. All had staging CT scans and were treated with radiotherapy. Median follow-up was 8.3 years. Seventy-four percent showed undifferentiated histology. In this cohort, 187 (47%) had RLN metastases. Multivariate analysis showed that RLN conferred a higher hazard for distant metastasis (p = .04). Using the Kaplan–Meier method, patients with N0 disease and RLN had a similar hazard for distant metastases as patients with N1 disease when compared with patients with N0 disease and without RLN. Conclusion Patients with N0 disease and RLN appear to share a similar prognosis to patients with N1 disease. © 2009 Wiley Periodicals, Inc. Head Neck, 2009 [ABSTRACT FROM AUTHOR]

The article focuses on the treatment of nasopharyngeal carcinoma (NPC) which is highly reactive to several chemotherapeutic agents. A three-drug combination chemotherapy, which constitutes of gemcitabine, paclitaxel, and carboplatin, was proposed to treat patients with metastatic NPC. In the study of 28 patients, it notes that toxicities generally came from bone marrow suppression including neutropenia, anemia, and thrombocytopenia.

Background.We sought to assess the efficacy and complications of linear accelerator-based stereotactic radiosurgery (SRS) plus intracavitary irradiation (ICI) as salvage treatment for local persistent and recurrent nasopharyngeal carcinoma (NPC) after primary external beam radiotherapy (EBRT). Methods.Between July 1995 and June 2003, 36 patients (25 men and 11 women; median age, 48 years; range, 22–66 years) with local recurrent NPC confined to the nasopharynx (rT1) or limited extension to the parapharynx and nasal cavity (rT2) were treated with SRS plus ICI. Nineteen patients had rT1 and 17 had rT2 disease. Five patients (13.8%) had persistent disease, and 31 patients (86.1%) had recurrent disease using the definition of >4 months after the primary treatment as recurrent relapse. The median target volume was 36.3 cm3 (range, 10.3–56.2 cm3) for the SRS treatment. All patients received 18 Gy to the 90% isodose line followed by two separate ICI 6 Gy each to 0.5 cm from the surface of the endotracheal balloon. Patients were assessed with serial nasoendoscopy and repeat scans (CT or MRI) at 3 months, and suspicious lesions were rebiopsied. Results.The median follow-up for surviving patients was 4.24 years (range, 0.73–8.81 years). Twenty-two of 36 (61%) patients were alive at the time of reporting. Twenty patients were free of disease, and two patients were alive with disease. Fourteen of 36 (39%) patients had died (five of distant metastases, six of local recurrences, two of both local disease and distant metastases, and one of unrelated cause). Patients with rT1 disease (median survival not reached) fared better that patients with rT2 disease (median survival, 4.6 years). The actuarial 5-year disease-free survival and overall survival (OS) were 57% (rT1 78%, rT2 39%) and 62% (rT1 80%, rT2 48%), respectively. The actuarial 5-year local control was 65% (rT1 82%, rT2 49%). The treatment was well tolerated with no significant acute complications. Sixteen patients (44%) had late complications, including palatal fibrosis in six patients (17%), trismus in seven patients (20%), cranial nerve palsies in seven patients (20%), temporal lobe necrosis in two patients (8%), and osteoradionecrosis of the skull base in six patients (17%). The complication-free survival rates at 2 and 5 years were 70% (95% confidence interval [CI], 56% to 87%) and 31% (95% CI, 17% to 56%), respectively. No patient died as a direct result of the late complication. Conclusion.Although our series is small, the combination of SRS and ICI seems to be an effective salvage treatment for early-stage recurrent NPC. The OS of 62% at 5 years is very encouraging and favorable compared with reported reirradiation or surgical series. The late complications are considerable but expected because of the high doses of radiation previously delivered. The ideal dose fractionation for SRS and ICI is unknown and remains to be defined. © 2005 Wiley Periodicals, Inc. Head Neck28: 321–329, 2006 [ABSTRACT FROM AUTHOR]

Purpose Materials and methods Results Conclusions The purpose of this study was to evaluate the radiotherapy planning feasibility of dose escalation with intensity‐modulated proton therapy (IMPT) to hypoxic tumor regions identified on 18F‐Fluoromisonidazole (FMISO) positron emission tomography and computed tomography (PET‐CT) in NPC.Nine patients with stages T3‐4N0‐3M0 NPC underwent 18F‐FMISO PET‐CT before and during week 3 of radiotherapy. The hypoxic volume (GTVhypo) is automatically generated by applying a subthresholding algorithm within the gross tumor volume (GTV) with a tumor to muscle standardized uptake value (SUV) ratio of 1.3 on the 18F‐FMISO PET‐CT scan. Two proton plans were generated for each patient, a standard plan to 70 Gy and dose escalation plan with upfront boost followed by standard 70GyE plan. The stereotactic boost was planned with single‐field uniform dose optimization using two fields to deliver 10 GyE in two fractions to GTVhypo. The standard plan was generated with IMPT with robust optimization to deliver 70GyE, 60GyE in 33 fractions using simultaneous integrated boost technique. A plan sum was generated for assessment.Eight of nine patients showed tumor hypoxia on the baseline 18F‐FMISO PET‐CT scan. The mean hypoxic tumor volume was 3.9 cm3 (range .9–11.9cm3). The average SUVmax of the hypoxic volume was 2.2 (range 1.44–2.98). All the dose‐volume parameters met the planning objectives for target coverage. Dose escalation was not feasible in three of eight patients as the D0.03cc of temporal lobe was greater than 75GyE.The utility of boost to the hypoxic volume before standard course of radiotherapy with IMPT is dosimetrically feasible in selected patients. Clinical trials are warranted to determine the clinical outcomes of this approach. [ABSTRACT FROM AUTHOR]

The article lists the name of the reviewers who are recipients of 2016 Outstanding Reviewer Recognition Program including Christopher Anderson, Sunil Badve and Lyle Broemeling.

The article lists several reviewers who volunteered to the journal's 2018 issue, who include Virgil Chan, Eric Hau, and Martin Borg.

A list of authors and peer reviewers such as Shabbir Alibhai, Jay Fisher and Bruno Medeiros of the journal who reviewed the journal from September 1, 2014, through August 31, 2015 is presented.

People who the author would like to thank for their assistance in the creation of the journal "Cancer" are mentioned.

The article presents information on religion and child abuse. The association of religion and child abuse is the subject of a recent book written by Philip Greven a historian and author of "Spare the Child: The Religious Roots of Punishment and the Psychological Impact of Physical Abuse." One has been considering the physical abuse of children and its implications for religion, focusing on the role played by physical punishment in the child's internalization of a God who is both loved and feared. However, if one were to limit one's attention to physical abuse, danger that adults who do not abuse their children physically for religious reasons will merely take comfort in this fact. Religious moderates and liberals alike have traditionally advocated some form of physical punishment, but his book has generally been viewed as a critique particularly of Christian conservatives and fundamentalists, both because religious legitimation of the physical punishment of children is widely known to be a centerpiece of certain conservative and fundamentalist theologies and because he argues that there is a psychodynamic connection between physical abuse and apocalypticism. Thus, in the interests of making all Christians, including moderates and liberals, uncomfortable,the author shifts his focus from Grevens concern with the religious roots of the physical abuse of children to the more direct role of religious ideas and beliefs in the traumatizing of children.